BioCentury
ARTICLE | Clinical News

Janssen halts trials of FAAH inhibitor

January 21, 2016 1:51 AM UTC

The Janssen Research & Development LLC unit of Johnson & Johnson suspended dosing of fatty acid amide hydrolase ( FAAH) inhibitor JNJ-42165279 in two Phase II trials. The decision follows the death of a healthy volunteer who received a different company's FAAH inhibitor in a French Phase I trial.

Janssen spokesperson Greg Panico told BioCentury about 120 patients have been treated to date with JNJ-42165279, and said Janssen has not received any reports of serious adverse events. ...